UAMS Psychiatric Research Institute
Little Rock, Arkansas, 72205, United States
NCT Number: NCT01371851
Psychostimulant dependence is a major public health problem and no medications have been shown to be very effective in treating this disorder. Thus, the investigators wish to study whether a blood pressure drug thought to reduce drug craving through its interaction at particular adrenergic receptors - doxazosin - can dredge cocaine use relative to placebo in psychostimulant dependent participants enrolled in an 8-week, randomized, double blind, placebo-controlled outpatient clinical trial. Our hypothesis is that doxazosin will reduce cocaine use relative to placebo in psychostimulant dependent participants.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1 / Phase 2
Little Rock, Arkansas, 72205, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
Time frame: twice-weekly urine samples (8 weeks)
Urine samples positive for methamphetamine or cocaine via twice-weekly urine drug screens. Weekly urine results data were averaged within subjects and the mean proportion across subjects within each group was calculated for graphic representation.
University of Arkansas
Other
Clinical Efficacy of Doxazosin for Psychostimulant Dependence
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05857852
Chemically-Induced Disorders, Cocaine Abuse
Charlottesville, Virginia, United States
View Trial DetailsNCT02037126
Chemically-Induced Disorders, Cocaine-Related Disorders
Birmingham, Alabama, United States
View Trial DetailsNCT04843046
Chemically-Induced Disorders, Cocaine Use Disorder
Houston, Texas, United States
View Trial DetailsNCT05262270
Chemically-Induced Disorders, Cocaine Use Disorder
Birmingham, Alabama, United States
View Trial Details